Search





Search





Markets
/
Stocks
/
nasdaq-pfe
/

Pfizer Inc

PFE

Add to Watchlist

27.560USD

+0.340+1.25%

Close 04/17, 16:00（ET）Quotes delayed by 15 min

156.71BMarket Cap

20.15P/E TTM



Pfizer Inc

27.560

+0.340+1.25%

Overview Financials Analysis Company

Overview

Financials

Analysis

Company

View Detailed Chart

Intraday

30m

Today

+1.25%

5 Days

+2.38%

1 Month

+0.40%

6 Months

+12.44%

Year to Date

+10.68%

1 Year

+24.48%

TradingKey Stock Score of Pfizer Inc

Currency: USD Updated: 2026-04-17

Key Insights

Pfizer Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 29.14.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pfizer Inc's Score

Industry at a Glance

Industry Ranking

63 / 156

Overall Ranking

151 / 4524

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pfizer Inc Highlights

StrengthsRisks

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 62.58B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.

Overvalued

The company’s latest PE is 20.15, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.85B shares, decreasing 2.42% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 118.37K shares of this stock.

Analyst Rating

Based on 32 analysts

Hold

Current Rating

29.137

Target Price

+7.16%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pfizer Inc News

China Adds Eli Lilly and Pfizer to Its First Private Insurance List — Is This a Buying Opportunity for Biotech Investors?

TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).

TradingKeyMon, Dec 8

[Reuters Breakingviews] Obesity kings’ buffet is slimmer than it looks

Obesity kings’ plump future is under siege. Over the past month Roche ROG.S and Pfizer PFE.N have splurged over $10 billion scooping up promising treatments and other rivals are rapidly developing their own medicines. Incumbents $242 billion Novo Nordisk NOVOb.CO and $722 billion Eli Lilly LLY.N may

ReutersThu, Oct 2